- Home
- CZNC vs ADCT Comparison
CZNC vs ADCT Comparison
Compare CZNC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- ADCT
- Stock Information
- Founded
- CZNC 1864
- ADCT 2011
- Country
- CZNC United States
- ADCT Switzerland
- Employees
- CZNC N/A
- ADCT N/A
- Industry
- CZNC Major Banks
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- ADCT Health Care
- Exchange
- CZNC Nasdaq
- ADCT Nasdaq
- Market Cap
- CZNC 297.0M
- ADCT 241.0M
- IPO Year
- CZNC N/A
- ADCT 2020
- Fundamental
- Price
- CZNC $19.41
- ADCT $3.08
- Analyst Decision
- CZNC
- ADCT Strong Buy
- Analyst Count
- CZNC 0
- ADCT 6
- Target Price
- CZNC N/A
- ADCT $7.80
- AVG Volume (30 Days)
- CZNC 34.1K
- ADCT 865.5K
- Earning Date
- CZNC 08-06-2025
- ADCT 08-05-2025
- Dividend Yield
- CZNC 5.73%
- ADCT N/A
- EPS Growth
- CZNC 15.34
- ADCT N/A
- EPS
- CZNC 1.75
- ADCT N/A
- Revenue
- CZNC $108,114,000.00
- ADCT $75,817,000.00
- Revenue This Year
- CZNC $6.78
- ADCT $11.75
- Revenue Next Year
- CZNC $4.59
- ADCT $10.29
- P/E Ratio
- CZNC $11.19
- ADCT N/A
- Revenue Growth
- CZNC 5.33
- ADCT 10.49
- 52 Week Low
- CZNC $17.25
- ADCT $1.05
- 52 Week High
- CZNC $22.68
- ADCT $3.98
- Technical
- Relative Strength Index (RSI)
- CZNC 49.61
- ADCT 54.11
- Support Level
- CZNC $19.28
- ADCT $3.04
- Resistance Level
- CZNC $20.04
- ADCT $3.39
- Average True Range (ATR)
- CZNC 0.44
- ADCT 0.21
- MACD
- CZNC -0.03
- ADCT 0.00
- Stochastic Oscillator
- CZNC 38.69
- ADCT 67.07
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).